Nuvalent Inc
NUVL77.110USD
-0.650-0.84%
交易中 （美东）报价延迟15分钟
5.53B总市值
亏损市盈率 TTM
关于 Nuvalent Inc 公司
Nuvalent, Inc. 是一家临床阶段的生物制药公司，专注于为临床验证的癌症激酶靶点开发精准靶向疗法。该公司开发的小分子具有克服耐药性、最大程度减少不良事件、解决脑转移和推动更持久反应的潜力。该公司正在推进强大的产品线，其中包括针对 ROS1 阳性、ALK 阳性和 HER2 阳性非小细胞肺癌的在研候选药物以及多个发现阶段的研究项目。其候选产品 NVL-520 正在为 ROS 原癌基因 1 (ROS1) 阳性非小细胞肺癌 (NSCLC) 患者开发。NVL-520 是一种新型 ROS1 选择性抑制剂。其候选产品 NVL-655 正在为间变性淋巴瘤激酶 (ALK) 阳性 NSCLC 患者开发。LC。NVL-655 是一种脑渗透性 ALK 选择性抑制剂。其候选产品 NVL-330 是一种脑渗透性人表皮生长因子受体 2 (HER2) 选择性抑制剂。
公司简介
公司代码NUVL
公司名称Nuvalent Inc
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
员工数量142
证券类型Ordinary Share
年结日Jul 29
公司地址One Broadway, 14Th Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话18573577000
网址https://www.nuvalent.com/
公司代码NUVL
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
持股股东
持股股东
占比
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
股东类型
持股股东
占比
Hedge Fund
48.82%
Investment Advisor
35.80%
Investment Advisor/Hedge Fund
19.30%
Individual Investor
2.87%
Private Equity
2.46%
Research Firm
1.99%
Venture Capital
0.77%
Sovereign Wealth Fund
0.48%
Pension Fund
0.25%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
438
74.96M
112.94%
-1.46M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
2023Q1
202
57.17M
111.42%
-2.69M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deerfield Management Company, L.P.
17.99M
27.11%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
9.70M
14.61%
+99.92K
+1.04%
Mar 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.94%
-93.95K
-1.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
6.68%
-60.03K
-1.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
4.11%
-65.91K
-2.36%
Mar 31, 2025
Commodore Capital LP
1.85M
2.79%
+233.40K
+14.39%
Mar 31, 2025
Shair (Matthew)
1.64M
2.48%
+2.65K
+0.16%
Jun 18, 2025
Perceptive Advisors LLC
1.63M
2.46%
-986.01K
-37.63%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
1.45M
2.18%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.44M
2.17%
+157.81K
+12.28%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Oncology ETF
3.99%
ALPS Medical Breakthroughs ETF
3.42%
Global X Guru Index ETF
1.27%
SPDR S&P Biotech ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
ProShares Ultra Nasdaq Biotechnology
0.56%
Invesco Nasdaq Biotechnology ETF
0.56%
iShares Health Innovation Active ETF
0.54%
Direxion Daily S&P Biotech Bull 3X Shares
0.53%
iShares Biotechnology ETF
0.35%
查看更多
Tema Oncology ETF
占比3.99%
ALPS Medical Breakthroughs ETF
占比3.42%
Global X Guru Index ETF
占比1.27%
SPDR S&P Biotech ETF
占比0.93%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.88%
ProShares Ultra Nasdaq Biotechnology
占比0.56%
Invesco Nasdaq Biotechnology ETF
占比0.56%
iShares Health Innovation Active ETF
占比0.54%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.53%
iShares Biotechnology ETF
占比0.35%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
